Literature DB >> 28160129

Hypersexuality in men with prolactinomas treated with dopamine agonists.

Irina Bancos1, Todd B Nippoldt2, Dana Erickson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28160129     DOI： 10.1007/s12020-017-1247-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  4 in total

Review 1.  Evidence-based endocrinology: illustrating its principles in the management of patients with pituitary incidentalomas.

Authors:  I Bancos; N Natt; M H Murad; V M Montori
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-02       Impact factor: 4.690

2.  Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.

Authors:  Thomas J Moore; Joseph Glenmullen; Donald R Mattison
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

3.  Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.

Authors:  Sunita M C De Sousa; Ian M Chapman; Henrik Falhammar; David J Torpy
Journal:  Endocrine       Date:  2016-09-06       Impact factor: 3.633

4.  Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.

Authors:  Irina Bancos; Michael R Nannenga; J Michael Bostwick; Michael H Silber; Dana Erickson; Todd B Nippoldt
Journal:  Clin Endocrinol (Oxf)       Date:  2013-12-16       Impact factor: 3.478
  4 in total
  2 in total

1.  Hypersexuality as a tip of the iceberg of a primary psychopathology: a joined position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) and of the Italian Society of Psychopathology (SOPSI).

Authors:  E Limoncin; G Ciocca; G Castellini; A Sansone; F Cavalieri; F Cavallo; T Cocchiaro; V Ricca; G di Lorenzo; A Rossi; A D Fisher; V Rochira; G Corona; E A Jannini
Journal:  J Endocrinol Invest       Date:  2022-05-09       Impact factor: 5.467

2.  Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.

Authors:  Emir Celik; Hande Mefkure Ozkaya; Burc Cagri Poyraz; Tarik Saglam; Pinar Kadioglu
Journal:  Endocrine       Date:  2018-09-11       Impact factor: 3.633
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.